Using blood purification therapy for critically ill patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry aims to identify subpopulations of critically ill patients who benefit most from extracorporeal blood purification (EBP) therapies, particularly focusing on the oXiris membrane. The study collects data from over 50 centers worldwide, utilizing a web-based platform that facilitates easy data entry and enhances collaboration among clinicians. It includes decision support tools to help personalize treatment at the bedside, thereby integrating clinical practice with research. The goal is to clarify the efficacy of EBP in removing inflammatory mediators and improving outcomes in patients with conditions like acute kidney injury and sepsis.

Why it matters

Who can join: the full rules

Inclusion Criteria: patients who meet all the following inclusion criteria may be included in this study:

1. Admission to ICU
2. Indications for at least one of the following extracorporeal blood purification treatments:

   1. Continuous Renal Replacement Therapy (CRRT) / Intermittent Hemodialysis (IHD) / Hybrid therapies for renal support/replacement;
   2. Immunomodulation therapy in critically ill patients using hemodiafilters with larger pore sizes characterized by enhanced transmembrane clearance of larger molecules (such as cytokines), hemodiafilters with enhanced unselective absorption of cytokines and/or endotoxins, cartridges with enhanced absorption of cytokines and/or endotoxins, techniques aimed at improving extracorporeal removal of cytokines and/or endotoxins.

It should be underlined that the lack of established guidelines on the use of membranes for extracorporeal blood purification (and on RRTs in general) leads to variability in clinical practice and treatments are initiated in accordance with the judgement of the responsible physician. Under these circumstances, it is preferable to keep inclusion criteria as wide as possible so as to obtain a real picture of clinical practice worldwide.

Exclusion Criteria: besides contraindications to the use of the EBP adopted (as from the manual of instructions), there are no exclusion criteria.

Where it's running

• Azienda Ospedaliero Universitaria Careggi
  Florence, Italy Recruiting

Study contacts

• Principal investigator: Gianluca Villa, md — University of Florence, Florence, Italy
• Study coordinator: Gianluca Villa, MD
• Email: gianluca.villa@unifi.it
• Phone: +393207615547

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating blood purification therapies in critically ill patients

  This study is testing if certain blood purification treatments can help critically ill patients with kidney problems or multiple organ failure feel better and recover faster.

  Recruiting at 15 sites Careggi Hospital · Empoli, Firenze and 14 other locations · NCT04033224

• Peripheral Perfusion Index trajectory to predict 28-day mortality in sepsis patients in the ICU

  This study tests whether changes in a finger-based perfusion index over the first 24 hours in the ICU can predict 28-day death among adults with sepsis or septic shock.

  Recruiting at 2 sites Trakya University · Edirne, Merkez and 1 other locations · NCT07740304

• Metabolic and Functional Study of γδ T Cells in Critically Ill Patients

  Researchers will look at how γδ T cells behave in severely ill patients, including those with sepsis, to see how their metabolism and function change.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Outside of the US · NCT07680816

• Understanding how patients tolerate fluid removal during kidney support in the ICU

  This observational study tests how well critically ill adults with acute kidney injury tolerate net fluid removal during continuous renal replacement therapy.

  Recruiting at 3 sites Hospital Las Higueras · Salvador and 9 other locations · NCT07643597

• Which antibiotic combo is safer for kidneys in serious hospital infections

  This trial tests whether vancomycin with piperacillin/tazobactam is gentler on the kidneys than other common broad-spectrum antibiotics for adults with serious infections in the hospital.

  Recruiting at 5 sites Phase 4 Bassett Healthcare · Worcester, Massachusetts and 6 other locations · NCT07556107

• Sodium bicarbonate for critically ill patients with metabolic acidosis and AKI

  This trial tests whether giving sodium bicarbonate helps reduce major kidney problems 90 days later in adults with septic or critical illness and kidney injury.

  Recruiting Phase 4 Universität Münster · Münster · NCT07464431

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.